IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Boehringer to Acquire California Biotech Firm

1:35 PM MDT | June 30, 2008 | Deepti Ramesh

Boehringer Ingelheim says it has agreed to acquire privately owned biopharmaceutical company Actimis Pharmaceuticals (San Diego) for as much as $515 million, depending on the successful development of an Actimis asthma drug. The deal is to be done in phases, depending on the progress of the asthma compound AP768, which is in phase 1 of clinical development. If AP768 successfully advances into phase III, Boehringer Ingelheim will own 100% of Actimis’ shares, Boehringer Ingelheim says. Actimis focuses on R&D of small-molecule therapeutics for severe...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa